Professionals 241 Users Online

Gamma Knife Market

Rising Prevalence of Brain Tumors Drives Growth in Gamma Knife Market

Gamma Knife Market by Disease Indication (Brain Metastasis, Cancer, Arteriovenous Malformation (AVM) and Trigeminal Neuralgia)

Gamma Knife Market Outlook (2023 to 2033)

The Global revenue from the Gamma Knife Market was around US$ 185.7 Million in 2022, with the global market expected to grow at a CAGR of 4.8% to reach a valuation of around US$ 311.4 Million by the end of 2033.

Market Size (2023)

US$ 194.7 Million

Projected Market Value (2033)

US$ 311.4 Million

Global Market Growth Rate (2023 to 2033)

4.8% CAGR

Market Share of Top 5 Countries


As assessed by Persistence Market Research, the gamma knife procedure is used to treat the head region predominantly. This segment, thus, held a market share of around 88.6% in the global market, in 2022. Overall, gamma knife market sales account for around 2.9% of revenue share in the global radiotherapy market, which was valued at around US$ 6.3 Billion in 2022.

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Sales Analysis of Market from 2017 to 2022 Vs Market Outlook for 2023 to 2033

The global market recorded a historic CAGR of 4.5% in the last 5 years from 2017 to 2022.

One of the main drivers of market expansion for the gamma knife is anticipated to be the rise in obesity cases around the world. Due to the non-invasive nature of the gamma knife procedure, the doctors are encouraging obese patients to choose it as their treatment option. According to a report, non-invasive procedures have more than 50% of the market share for aesthetic medicine, which opens up a huge potential market for gamma knife procedures.

Stereotactic radiosurgery has been developed to treat cancers instead of the conventional craniotomy procedure. The Gamma knife method is currently being widely used. It doesn't harm healthy cells and solely targets tumor cells, therefore it has fewer adverse effects.

Elekta, for instance, introduced Elekta Esprit in May 2022, which gives clinicians much faster automated treatment planning as well as more individualized and patient-friendly treatments. Esprit also provides clinicians with better visualization, remote accessibility, and team communication options.

A significant portion of the population is being affected by a variety of neurological disorders due to the growing elderly population, including multiple sclerosis, Parkinson's disease, brain tumors, epilepsy, dementia, and stroke. In 2019, 1 in 11 individuals on the planet was over 65, and by 2050, this number will almost quadruple to 1 in 6. This information comes from a UN report. The prevalence of neurological disorders is rising quickly as the world's population ages.

  • The Alzheimer's Association estimates that 6.5 million U.S. citizen aged 65 and older were suffering from Alzheimer's in 2022. By 2060, this number could increase to 13.8 million. According to the Parkinson's Foundation's estimates, there are currently about 1 million people living with Parkinson's disease in the U.S., and as the population ages, this number is projected to rise to 1.2 million by 2030. Thus, the growing prevalence of cognitive disorders will demand surgical procedures for treatment and cure purpose such as gamma knife radiosurgery, ultimately leading to market growth.

Gamma radiation beams are targeted on the exact site of the tumor during gamma knife radiosurgery, a form of radiation therapy. The therapy can be done in a single session because it is a non-invasive process that requires very little recovery time. Complex neurological disorders are best treated using this method, which has no surgical incisions during the entire procedure and is completely painless. The quick recovery time and non-invasive nature of the gamma knife surgery will aid in future market growth.

The global market is likely to show high growth over the coming years at a CAGR of 4.8% and reach a global market size of US$ 311.4 Million by 2033.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

How Can the Global Market Grow?

“Rising Prevalence of Brain Tumors Coupled with Introduction of Various Combination Treatment Therapies”

According to the American Cancer Society, brain tumors are the eighth most prevalent type of cancer and the third most common cause of cancer deaths in people aged 40 and older. The demand for brain tumor treatment and rehabilitation is anticipated to rise dramatically as the population ages and expands, which will favorably influence market growth.

Clinicians decided against whole brain radiation therapy (WBRT) since it might result in cognition abnormalities due to the patient's age and overall wellness. The ability to provide a high integral dosage to the tumor with a rapid dose fall-off into nearby healthy brain tissue makes gamma knife radiosurgery a suitable treatment for numerous brain metastases. Additionally, biological and immunological agents can be used in conjunction with Gamma Knife radiosurgery.

  • For instance, Elekta developed a combination therapy for melanoma brain metastases. Immunotherapy and gamma knife radiosurgery brought about a full remission of the patient's intracranial and systemic metastases. Patients with melanoma brain metastases have shown improved tumor control and survival with this combo therapy.

Formal guidelines apply to new launches and introduction in the gamma knife market, and regulatory permission is required before items may be introduced to the market. Leading companies in the gamma knife market have launched a variety of devices in recent years due to regulatory licenses they have gained in key geographic markets.

  • Icon was released by Elekta in May 2022. With the introduction of Icon, it revolutionised the use of gamma life technology by introducing frameless, mask-based radiosurgery. Additionally, because of its dosimetric and efficiency advantages over other technologies, it boosted the market in Australia by treating patients suffering from neurological diseases by increasing brain SRS capacity in patients.
Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Can the Market Growth Be Affected in Any Way?

High Cost of Gamma Knife Radiotherapy Machines Coupled with Low Awareness of Patients

The high cost of gamma knife machines and substantial investment and maintenance cost associated with these machines will result in low adoption of these treatment in emerging economies, as a result the market will face impedance. Gamma knife machines are more expensive than other radiation equipment.

  • For instance, in India, gamma knife surgery starts at USD 6500 (INR 483,000). In western countries including the U.S., the U.K., and Canada, the price of the same surgery ranges from $40000 to $70000. Gamma knife's radiation source, cobalt 60, costs between US$1 million to US$2 million and must be replaced every five years. Gamma knife radiation has initial expenses that total roughly around US$ 7 million.

Manufacturers of gamma knife devices are mainly located in the Americas and Europe. This has a negative impact on the availability of the product across the globe. Additionally, the market's expansion is somewhat constrained by a dearth of skilled specialists who can operate gamma knife equipment.

The general awareness of gamma-knife treatment is also ambiguous. The many benefits of gamma knife radiation are not well understood by patients all across the world. Some patients view the procedure as invasive, while others object to the use of gamma radiation during surgery, the low awareness of gamma knife procedures is also expected to slow down the market growth.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Country-wise Insights

Why is the U.S. Market Booming?

“Prevalence of Cancer”

The U.S. accounted for around 12.7% market share in the global market in 2022.

The country's market expansion is reportedly being driven by an increase in cancer cases. According to information from Cancer Data & Statistics, there were more than 1.7 million new cases of cancer reported in the U.S. alone in 2022.

Furthermore, the gamma knife procedure is less invasive than many other types of treatment, which makes it the preferred decision. Additionally, as the technique becomes more accessible due to rising disposable income, market growth is anticipated to continue in the nation.

Will the Germany Be a Lucrative Market for Gamma Knife?

“Increasing Cases of Alzheimer’s Disease”

The Germany market held around 8.2% market share of the global market in 2022.

An increase in Alzheimer's disease patients is the primary factor driving the market. According to figures from the Alzheimer's Association, more than 1.5 million people in Germany are affected by the disease.

In addition, the major companies in the gamma knife industry are modifying the current models with the most recent technologies. They have been granting capitals to researchers to develop novel procedures, which is further influencing the market to grow.

How is Japan Emerging as a Prominent Market?

“Increasing Instances of Vascular Abnormalities”

Japan held a market share of about 5.6% of the global market in 2022.

The market share is anticipated to rise as a result of an increase in vascular abnormality instances. Numerous citizens of the country experience issues with their veins and arteries as a result of their way of life.

In addition, Japan's healthcare industry has undergone a significant technological upgrade. The leading players are able to maintain their competitive edge over competitors from other regions as a result of this the gamma knife market is expected to grow throughout the forecast period.

Category-wise Insights

Which Disease Indication Segment is Driving the Global Market?

“Increasing Rates of Brain Cancer”

The brain metastasis segment held around 69.2% share of the total market in 2022.

The market share of the brain metastasis segment is anticipated to rise as a result of an increase in cancer cases, particularly cerebrum malignancy, and an improvement in the medical infrastructure.

According to a WHO survey, around 10 million people died from cancer in 2020, making it the leading cause of death globally. The important thing to remember in this case is that a significant portion of the market is made up by brain cancer. In addition, when a patient's cancer has progressed to stage 4, there is a significant possibility that it will have gone to the patient's brain. All of these elements are anticipated to increase segment's market share even more.

Which Organ Treated Segment is Dominant Within the Global Market?

“Increased Demands for Non-Invasive Procedures”

The head segment held around 88.6% share of the total market in 2022.

The increased use of non-invasive methods in general can be credited with the increasing share of the head segment. When treating brain tumors, the adoption rate increases. Other than that, the procedure's adverse effects are virtually non-existent.

Additionally, the highest level of efficiency is guaranteed by the use of computer directed therapy equipment. This ensures that the success rate stays high in comparison to many other procedures, together with the great precision with which the beam penetrates the target location.

Competition Landscape

By investing in mergers and acquisitions, the major market players are aiming to strengthen their position. In addition, the players are making investments in strategic alliances with competitors in other markets.

Some key instances of development include:

  • In May 2022, Elekta launched Elekta Esprit, the company's most advanced system, a next-generation stereotactic radiosurgery system that offers clinicians much faster, automated treatment planning and more individualized, patient-friendly procedures.
  • In May 2020, Elekta launched Leksell Gamma Knife Lightning, which was the only highly integrated computerized treatment management system for gamma knives that enabled plan-optimization based on factors like beam on-time limits.

Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the gamma knife market, which are available in the full report.

Gamma Knife Industry Report Scope



Forecast Period


Historical Data Available for


Market Analysis

USD Million for Value

Key Countries Covered

  • U.S.
  • Canada
  • Brazil
  • Argentina
  • Mexico
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Russia
  • India
  • Thailand
  • Malaysia
  • Indonesia
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Türkiye
  • GCC
  • North Africa
  • South Africa

Key Market Segments Covered

  • Disease Indication
  • Organ Treated
  • Region

Key Companies Covered

  • Elekta AB
  • Varian Medical Systems
  • Huiheng Medical, Inc.
  • MASEP Medical Science Technology Development (Shenzhen) Co., Ltd.
  • Akesis Inc.
  • Cyber Medical Corporation Limited.
  • Masep Infini Global, Inc.
  • Nordion, Inc.
  • Hokai
  • ET Medical Group
  • American Shared Hospital Services

Report Coverage

  • Market Forecast
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Key Segments Covered in Gamma Knife Industry Research

Disease Indication:

  • Brain Metastasis
  • Cancer
  • Arteriovenous Malformation (AVM)
  • Trigeminal Neuralgia
  • Others

Organ Treated:

  • Head
  • Neck
  • Others


  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

- Companies Covered in This Report -

  • Elekta AB
  • Varian Medical Systems
  • Huiheng Medical, Inc.
  • MASEP Medical Science Technology Development (Shenzhen) Co., Ltd.
  • Akesis Inc.
  • Cyber Medical Corporation Limited.
  • Masep Infini Global, Inc.
  • Nordion, Inc.
  • Hokai
  • ET Medical Group
  • American Shared Hospital Services

- Frequently Asked Questions -

The global market is currently valued at around US$ 185.7 Million in 2022.

Sales of the market are set to witness growth at a CAGR of 4.8% and be valued at around US$ 194.7 Million by 2033.

Demand for the global market increased at a 4.5% CAGR from 2017 to 2022.

The global market is projected to reach a valuation of around US$ 194.7 Million by the end of 2023.

The U.S., Germany, the U.K., China, and Japan account for most demand within the market, currently holding around 40.8% market share.

The U.S. accounts for around 12.7% share of the global market in 2022.

Japan held a market share of about 5.6% of the global market in 2022.

The Germany market held around 8.2% market share of the global market in 2022.

Elekta AB, Varian Medical Systems, Huiheng Medical, Inc., MASEP Medical Science Technology Development (Shenzhen) Co., Ltd., Akesis Inc., Cyber Medical Corporation Limited., Masep Infini Global, Inc., Nordion, Inc., Hokai, ET Medical Group and American Shared Hospital Services areealthcarehhhhh among others are the key players in the global market.

An increasing prevalence of lifestyle disorders such as cancer, obesity, and neurological disorders and surging adoption of gamma knifes in treating obesity are few of the factors propelling the global market.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate